{"protocolSection":{"identificationModule":{"nctId":"NCT06472271","orgStudyIdInfo":{"id":"colistin in neonates"},"organization":{"fullName":"Helwan University","class":"OTHER"},"briefTitle":"Colistin Dosage Prsonalization Approach","officialTitle":"Colistin in Neonatal ICU Patients With Gram Negative Resistant Infection: Dosage Personalization Approach"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-11-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-05-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-18","studyFirstSubmitQcDate":"2024-06-18","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-18","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Mahmoud I Mostafa","investigatorTitle":"Lecturer at pharmacy practice department","investigatorAffiliation":"Helwan University"},"leadSponsor":{"name":"Mahmoud I Mostafa","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"A few studies have evaluated higher doses or the administration or a loading dose, which is routine in adults, in pediatric patients, and reported improved colistin exposure without an increased risk of nephrotoxicity The main questions it aims to answer are What is the optimal dosing strategies of intravenous colistin for the treatment of multidrug-resistant gram-negative bacterial infections in preterm neonates? What is the incidence of AKI? What is the factors increasing AKI incidence? A single center retrospective and comparative study, cohort study compare low dose 5 mg/kg/day versus 7.5mg/kg/day","detailedDescription":"Retrospective study to measure safety and efficacy of colistin conventional dose versus high dose then prospective design to measure pharmacokinetics parameter of both doses to design optimal dose"},"conditionsModule":{"conditions":["Colistin Adverse Reaction"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"21 Days","designInfo":{"observationalModel":"COHORT","timePerspective":"OTHER"},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Conventional initial dose","description":"Colistin 5mg/kg/day","interventionNames":["Drug: Polymyxin e"]},{"label":"High initial dose","description":"Colistin 7.5mg/kg/day","interventionNames":["Drug: Polymyxin e"]}],"interventions":[{"type":"DRUG","name":"Polymyxin e","description":"Increased starting colistin dose","armGroupLabels":["Conventional initial dose","High initial dose"],"otherNames":["Colistin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Clinical response","description":"Resolving signs and symptoms with normalized acute phase reactants in clinical septic patients","timeFrame":"21 days"}],"secondaryOutcomes":[{"measure":"Microbiological clearance","description":"Negative culture results following Colistin therapy","timeFrame":"21 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Neonates aged between (0-30 days) born before 37 weeks\n* Critically ill patients with nosocomial infection with proven culture-resistant gram-negative bacteria.\n* Neonates who are indicated for colistin and started colistin therapy for at least 48 hr.\n\nExclusion Criteria:\n\n* Serum creatinine â‰¥1.5 baseline before colistin\n* Received colistin before NICU stay\n* Administration of concurrent nephrotoxic drugs including amphotericin, gentamicin, or amikacin.\n* Major congenital anomalies or with previous renal impairment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"0 Days","maximumAge":"28 Days","stdAges":["CHILD"],"studyPopulation":"Preterm, critically-ill, neonates diagnosed with resistant gram-negative infections","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Cairo univrsity Hospitals","status":"RECRUITING","city":"Cairo","zip":"11435","country":"Egypt","contacts":[{"name":"Doaa Hamed, PHD","role":"CONTACT","phone":"01062963529","email":"doaa.labib@cu.edu.eg"}],"geoPoint":{"lat":30.06263,"lon":31.24967}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"browseLeaves":[{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003091","term":"Colistin"},{"id":"D000011113","term":"Polymyxins"}],"ancestors":[{"id":"D000000900","term":"Anti-Bacterial Agents"},{"id":"D000000890","term":"Anti-Infective Agents"}],"browseLeaves":[{"id":"M6319","name":"Colistin","asFound":"Streptococcus","relevance":"HIGH"},{"id":"M13997","name":"Polymyxins","asFound":"Dysport","relevance":"HIGH"},{"id":"M4222","name":"Anti-Bacterial Agents","relevance":"LOW"},{"id":"M4214","name":"Anti-Infective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}